The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer
European Review for Medical and Pharmacological Sciences, cilt.26, sa.20, ss.7679-7686, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 20
- Basım Tarihi: 2022
- Doi Numarası: 10.26355/eurrev_202210_30044
- Dergi Adı: European Review for Medical and Pharmacological Sciences
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
- Sayfa Sayıları: ss.7679-7686
- Anahtar Kelimeler: Pan-immune inflammation value, PILE Score, Hepa-tocellular carcinoma, Overall survival
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
OBJECTIVE: We aimed at investigating the prognostic significance of a novel immune marker, PIV and PILE score (a score composite from PIV, LDH and ECOG PS), in patients with HCC in a single center. PATIENTS AND METHODS: 120 patients who met the criteria were included. PIV and PILE at the time of diagnosis were computed retrospectively. For PIV, the median value of 286.15 was taken as the cut-off. While <286.15 was considered low, ≥286.15 was considered high PIV. The PILE score included PIV (< median vs. ≥ median), lactate dehydrogenase level (